Cesarean section (CS) is a major surgical intervention that affects women at childbearing age. Scarring from CS potentially causes discomfort and psychological distress. Emerging evidence indicates that epidermal growth factor (EGF) plays crucial roles in wound healing with the potential of minimizing scar formation. This study aims to investigate the effect of microencapsulated recombinant human EGF (Me-EGF) in scar prevention. Silicone gel was incorporated as part of the routine scar treatment. Healthy women scheduled for cesarean delivery will be enrolled and randomized to three groups: (1) no scar treatment, (2) silicone gel only, or (3) silicone gel plus Me-EGF. Vancouver Scar Scale (VSS) will be used for scar assessment at the 6th month and 9th month after CS.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Vascularity
Timeframe: Evaluation of Vascularity is done at: month 3+ follow-up visit.
Pigmentation
Timeframe: Evaluation of Pigmentation is done at: month 3+ follow-up visit.
Pliability
Timeframe: Evaluation of Pliability is done at: month 3+ follow-up visit.
Height
Timeframe: Evaluation of Height is done at: month 3+ follow-up visit.
Vascularity
Timeframe: Evaluation of Vascularity is done at: month 6+ follow-up visit.
Pigmentation
Timeframe: Evaluation of Pigmentation is done at: month 6+ follow-up visit.
Pliability
Timeframe: Evaluation of Pliability is done at: month 6+ follow-up visit.
Height
Timeframe: Evaluation of Height is done at: month 6+ follow-up visit.
Vascularity
Timeframe: Evaluation of Vascularity is done at: month 9+ follow-up visit.
Pigmentation
Timeframe: Evaluation of Pigmentation is done at: month 9+ follow-up visit.
Pliability
Timeframe: Evaluation of Pliability is done at: month 9+ follow-up visit.
Height
Timeframe: Evaluation of Height is done at: month 9+ follow-up visit.